Previous Article | Next Article 
Journal of Virology, November 1999, p. 9456-9467, Vol. 73, No. 11
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus Type 1 Immediate-Early Protein
Vmw110 Inhibits Progression of Cells through Mitosis and from
G1 into S Phase of the Cell Cycle
Patrick
Lomonte* and
Roger D.
Everett
MRC Virology Unit, Glasgow G11 5JR, Scotland,
United Kingdom
Received 30 April 1999/Accepted 17 July 1999
 |
ABSTRACT |
Herpes simplex virus type 1 (HSV-1) immediate-early protein Vmw110
stimulates the onset of virus infection in a multiplicity-dependent manner and is required for efficient reactivation from latency. Recent
work has shown that Vmw110 is able to interact with or modify the
stability of several cellular proteins. In this report we analyze the
ability of Vmw110 to inhibit the progression of cells through the cell
cycle. We show by fluorescence-activated cell sorter and/or confocal
microscopy analysis that an enhanced green fluorescent protein-tagged
Vmw110 possesses the abilities both to prevent transfected cells moving
from G1 into S phase and to block infected cells at an
unusual stage of mitosis defined as pseudo-prometaphase. The latter
property correlates with the Vmw110-induced proteasome-dependent
degradation of CENP-C, a centromeric protein component of the inner
plate of human kinetochores. We also show that whereas Vmw110 is not
the only viral product implicated in the block of infected cells at the
G1/S border, the mitotic block is a specific property of
Vmw110 and more particularly of its RING finger domain. These data
explain the toxicity of Vmw110 when expressed alone in transfected
cells and provide an explanation for the remaining toxicity of
replication-defective mutants of HSV-1 expressing Vmw110. In addition
to contributing to our understanding of the effects of Vmw110 on the
cell, our results demonstrate that Vmw110 expression is incompatible
with the proliferation of a dividing cell population. This factor is of
obvious importance to the design of gene therapy vectors based on
HSV-1.
 |
INTRODUCTION |
Among the human pathogens, herpes
simplex virus type 1 (HSV-1) is one of the most extensively studied
viruses, yet biologically it remains incompletely understood. One of
its most interesting features is the dual life cycle that this virus
has adopted to maintain its survival. After the initial lytic infection
at the periphery, the virus will evade the host immune system by
infecting sensory neurons, where it can stay in a latent state lifelong (for a review, see reference 18). The lytic and
latent states differ by the number of transcriptionally active genes
that can be detected. All viral genes, numbering about 80, are
expressed from the 152-kb double-stranded genomic DNA during lytic
infection, but only one set of viral transcripts can be readily
detected during latency (19). The expression of the lytic
genes is temporarily regulated, with the genes classified as
immediate-early (IE), early, and late, depending on the time course of
their synthesis and requirement for prior viral gene expression and DNA
replication (40).
Five IE proteins are encoded by HSV-1, of which four regulate gene
expression during lytic infection. Vmw175 (ICP4) and Vmw63 (ICP27) have
been shown to be essential for virus replication (8, 9, 32, 36,
41, 53), whereas Vmw68 (ICP22) is dispensable for virus viability
in most cell types (35, 48). Vmw110 (ICP0) is a RING finger
protein which activates gene expression in a strong and promiscuous
manner in transfection assays and which can act synergistically with
Vmw175 (12). Mutant viruses either deficient for the
expression of Vmw110 or expressing an inactive form of the protein are
able to grow in cell culture. However, these viruses exhibit a cell
type- and multiplicity-dependent growth phenotype which affects the
onset of lytic infection and strongly decreases their probability of
initiating a productive infection (42, 51). A more definite
role of Vmw110 in influencing the latent-lytic switch has been
demonstrated in cultured cells (16, 20, 55, 57) as well as
in mouse latency models (5, 6, 30). Indeed, the absence of
Vmw110 causes a mutant virus to reactivate inefficiently from latency,
a defect overcome in vitro by providing exogenous Vmw110 (20,
57).
The study of the multiple effects of the IE proteins on the biology of
the virus as well as on the metabolism of host cells has constituted a
major challenge, which became more prominent with the development of
vector therapy aiming to use HSV-1 as a delivery system. The safety of
such vectors is of obvious concern, and among the several criteria that
have to be satisfied are lack of toxicity, genome persistence, and gene
expression. The first replication-defective mutants of HSV-1 with a
markedly reduced cytopathic effect independent of the multiplicity of
infection (MOI) were deficient for the expression of either Vmw175 or
Vmw63 (23). Infection of cells by HSV-1 mutants unable to
express both Vmw175 and Vmw63 in addition to either Vmw68
(56) or Vmw110 (44) led to a prolonged cell
survival and gene expression. The toxicity of other mutants unable to
express the virion structural transactivator protein Vmw65 (VP16 or
TIF) (1), Vmw65 and Vmw175 (24), or Vmw65 in
combination with mutations affecting both Vmw175 and Vmw110 (37,
38) were also investigated. A significant amount of cytotoxicity
was still retained by all these mutant viruses, suggesting that
mutation or reduction of the expression of all HSV-1 IE genes was
necessary to significantly reduce adverse effects on the cell. The work
of Samaniego et al. (45) showed that an HSV-1 mutant lacking
all five IE proteins was nontoxic to Vero and human embryonic lung
cells, but paradoxically the level of transgene expression in infected
cells was dramatically decreased. One of the major pieces of
information highlighted by these different studies was that although
Vmw110 is dispensable for virus replication in cell culture, infection
with a replication-defective mutant of HSV-1 expressing Vmw110
decreases cell survival. In addition, overproduction of Vmw110 in the
absence of Vmw175, Vmw63, and Vmw68 inhibited further growth of cell
cultures, suggesting that Vmw110 might inhibit cellular DNA synthesis
or cell cycle progression (56).
Several aspects of cell metabolism are affected by Vmw110. Proteins as
different as elongation factor 1
(25), the cell cycle
regulator cyclin D3 (26), and a ubiquitin-specific protease named HAUSP (14, 33) have been reported to interact with
Vmw110. Furthermore, Vmw110 is specifically implicated in the
proteasome-dependent degradation of several cellular proteins or
protein isoforms. This is the case for the catalytic subunit of the
DNA-dependent protein kinase, although the consequences of this
activity for both virus and cell biology have not been well defined
(29, 34). Specific isoforms of PML, a permanent component of
nuclear domains called ND10, PML nuclear bodies, or promyelocytic
oncogenic domains (PODs), are also targeted for degradation by Vmw110.
This process has been shown to correlate with the disappearance of the
ND10 domains in cells infected with wild-type HSV-1 or transfected with
a plasmid expressing Vmw110 (2, 14, 15). Finally, Vmw110 is
also directly implicated in the proteasome-dependent degradation of
CENP-C (17), a 140-kDa centromeric protein component of the
inner kinetochore plate which plays a critical role in cell division by
establishing and/or maintaining proper kinetochore size and stabilizing
microtubule attachments (10, 43, 52).
From these data, it is very likely that various aspects of the
metabolism of cells infected by wild-type HSV-1 or by any
replication-defective mutant expressing Vmw110 will be affected in ways
that can be directly attributed to the effect of Vmw110. In this
report, we investigate the effect of expression of Vmw110 on the cell
cycle. We show by fluorescence-activated cell sorter (FACS) analysis that the expression of an enhanced green fluorescent protein
(EGFP)-tagged Vmw110 in transfected cells blocks the
G1-to-S phase progression. We also analyze the progression
through mitosis of synchronized cells infected in G2 and
show that Vmw110 and more precisely the RING finger domain of Vmw110 is
directly implicated in blocking infected cells at a stage of mitosis
defined as pseudo-prometaphase.
 |
MATERIALS AND METHODS |
Plasmids and bacteria.
Plasmids expressing wild-type Vmw110
(pEG110) or the RING finger mutant Vmw110 protein FXE (pEGFXE) linked
at their N-terminal ends to EGFP were based on the pEGFP-C1 vector
(Clontech). Fusion proteins synthesized from plasmids pEG110 and pEGFXE
were called EG110 and EGFXE, respectively. Wild-type or RING finger
mutant Vmw110 genes were cloned in frame with the EGFP open reading
frame, and cloning regions were sequenced to verify the correct
orientation and in-frame position of Vmw110 genes (31).
Plasmids were grown in Escherichia coli DH5, and large-scale
preparations were made by the boiling method and CsCl purification.
Viruses and cells.
HSV-1 strain 17 syn+ was the parental
strain used in this study. Virus vEG110 expresses at both IE-1 loci the
full-length Vmw110 linked at its N-terminal end to EGFP; it was
constructed by cotransfection of infectious dl1403 DNA (as
described previously [11]) with plasmid p111E110
containing the Vmw110 gene fused with the EGFP gene and flanked at both
ends by the DNA sequences localized at each side of the Vmw110 gene in
the HSV-1 genome (31). Virus vEGdl110 is a
deletion mutant from which both Vmw110 gene copies have been removed
and replaced at both loci by the EGFP coding sequence, and virus vEGFXE
is a mutant virus expressing the EGFP version of the RING finger FXE
Vmw110 mutant protein; both were constructed in a manner similar that
used for vEG110 (31). Vmw110 mutant viruses
dl1403 and FXE (11, 51) were also used. vEG110,
vEGFXE, and vEGdl110 were genetically and biologically tested to ensure that their properties were identical to those of the
non-EGFP versions. Table 1 summarizes
several known biological characteristics of the wild-type, FXE, and
dl1403 viruses that were tested in parallel with vEG110,
vEGFXE, and vEGdl110 by immunofluorescence and/or Western
blotting to ensure that the latter viruses retain the same biological
properties than their non-EGFP counterparts. Furthermore, like the FXE
and dl1403 viruses, vEGFXE and vEGdl110 showed a
2-log decrease in their titers in human fetal lung cells compared to
baby hamster kidney cells, whereas vEG110 showed titers similar to
those of wild-type HSV-1 in both cell lines (results not shown). These
results indicate that EG110 was able to restore a growth phenotype
similar to that of the wild-type virus and taken together indicate that
EG110 retains the functions of the normal protein. All viruses were
grown and titrated in baby hamster kidney cells propagated in Glasgow
modified Eagle's medium containing penicillin (10 U/ml) and
streptomycin (100 µg/ml) and supplemented with 10% newborn calf
serum and 10% tryptose phosphate broth. HEp-2 cells were grown at
37°C in 5% CO2 in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum and antibiotics as specified
above.
Electroporation.
HEp-2 cells were trypsinized, resuspended
in complete medium, pelleted, and washed once with serum-free medium
before being resuspended in serum-free medium at a concentration of
7.5 × 106 cells per ml. Plasmid DNA (20 µg) and 0.8 ml of cells were added to a 4-mm electroporation cuvette, incubated on
ice for 10 min, mixed again, and pulsed in a Hybaid electroporator at a
setting of 400 V. Cells were incubated on ice for a further 10 min
before being diluted into fresh complete medium, seeded into two
35-mm-diameter dishes, and incubated at 37°C in 5% CO2.
Six to eight hours postelectroporation, the medium was taken out of the
dishes to remove dead cells and was replaced with fresh medium. Cells
were then left in the incubator until use.
FACS analysis.
HEp-2 cells were trypsinized at the
appropriate time postinfection or postelectroporation and resuspended
in complete medium. After centrifugation at 800 × g
for 5 min, cells were washed with 5 ml of cold phosphate-buffered
saline (PBS), centrifuged again, and resuspended in formaldehyde (1%
[vol/vol] in PBS containing 2% sucrose). After fixation on ice for
10 min, cells were centrifuged, washed once with PBS, and centrifuged
again. Pelleted cells were resuspended in 500 µl of a solution of
0.1% saponin (ICN), 0.5% bovine serum albumin (Sigma), propidium
iodide (PI; 100 µg/ml), and RNase A (100 µg/ml) in PBS. After 30 min of incubation on ice, the total DNA content was analyzed by a
FACScan analyzer using LYSYS II software (Becton Dickinson, San Jose,
Calif.).
Synchronization of cells.
Sequential thymidine and
aphidicolin blocking steps produced monolayers of synchronized HEp-2
cells. Cells were seeded at a density of 1.25 × 105
per 35-mm-diameter dish, usually containing four coverslips, depending
on the experiment to be performed. The next day, medium containing 2 mM
thymidine was substituted, and 12 h later cells were washed twice
and medium containing 0.025 mM thymidine and 0.025 mM deoxycytidine was
added. A further 12 h later cells were washed twice again and
refed with medium containing 2.5 µM aphidicolin. After another
14 h, cells were washed three times and refed with normal medium.
Infections were carried out at suitable time after release.
Immunofluorescence and confocal microscopy.
HEp-2 cell
coverslips prepared during synchronization experiments were put in
Linbro wells at the appropriate time after viral infection. Cells were
fixed with formaldehyde (5% [vol/vol] in PBS containing 2%
sucrose). If infections were carried out with viruses expressing an
EGFP, cells were permeabilized with 0.5% NP-40 in PBS with 10%
sucrose and 0.5 µg of PI per ml for 30 s. Cells were then washed
three times with PBS, and a final wash was done with distilled water
before mounting of the coverslips by using Citifluor. In the case of
infections with non-EGFP-expressing viruses, cells were permeabilized
for 5 min in a PBS solution containing 0.5% NP-40 and 10% sucrose.
Primary antibodies were diluted in PBS containing 1% newborn calf
serum. Monoclonal antibodies (MAbs) were used at dilutions of 1/1,000
(anti-Vmw110 MAb 11060 [13]) and 1/100 (anti-Vmw175
MAb 58S) [50]). After incubation at room temperature
for 1 h, coverslips were washed at least three times with PBS and
then treated with the fluorescein isothiocyanate-conjugated sheep
anti-mouse immunoglobulin G (Sigma) secondary antibody diluted at
1/100. After a further 30-min incubation, coverslips were washed three
times with PBS, incubated for 30 s in a solution of PBS containing
PI (0.5 µg/ml), washed again three times with PBS, and then washed
once with water before being mounted by using Citifluor. Cell samples
were examined in a Zeiss LSM 510 confocal microscope with two lasers
giving excitation lines at 543 and 488 nm. The data from the channels
were collected simultaneously with eightfold averaging at a resolution
of 1,024 by 1,024 pixels, using optical slices of 1 µm. The
microscope was a Zeiss Axioplan with either a 40× or a 63× oil
immersion objective lens. Data sets were processed with the LSM 510 software and then exported for preparation for printing by using Adobe Photoshop.
Western blotting.
Sodium dodecyl sulfate-polyacrylamide gels
(10%) were prepared and run in the Bio-Rad MiniProtean II apparatus
and then proteins were electrophoretically transferred to
nitrocellulose membranes according to the manufacturer's
recommendations. After blocking in PBS containing 0.1% Tween 20 (PBST)
and 5% dried milk overnight at 4°C, the membranes were incubated
with primary antibody in PBST-5% dried milk at room temperature for
1 h and then washed in PBST at least three times before incubation
with horseradish peroxidase-conjugated secondary antibody in PBST-2%
dried milk at room temperature for 1 h. After extensive washing,
filters were soaked in Amersham ECL reagent and exposed to film.
 |
RESULTS |
Vmw110 blocks transfected cells at the G1/S border of
the cell cycle.
HSV-1 infection has already been reported to block
G1-to-S phase progression of synchronized CV-1 cells
infected in the G1 phase of the cell cycle (7).
More recently, Wu et al. (56) suggested that Vmw110 might be
implicated in the inhibition of cell DNA synthesis in cells infected
with the replication-defective mutant of HSV-1, d95
(ICP4
ICP27
ICP22
). Based on
these data, we investigated the effect of the expression of Vmw110 on
the progression of cells from G1 into S phase of the cell
cycle. To enable a simple method of studying the effect of Vmw110 on
the cell cycle in the absence of all other viral components, we
constructed plasmids expressing wild-type and mutant forms of Vmw110
linked to EGFP (see Materials and Methods). HEp-2 cells were
electroporated with plasmid pEGFP, pEG110, or pEGFXE. Both EG110 and
EGFXE had been previously tested to ensure that their biological
properties were identical to those of the non-EGFP versions of the
proteins (reference 31 and Table 1). Cells were
harvested 17, 23, 27, and 30 h postelectroporation, and their DNA
content was quantified by FACS analysis to determine their distribution
in the cell cycle (Fig. 1, FL3-H). Cells
positive for the expression of an EGFP were easily detectable because
their position on the y axis of the dot plot diagram (Fig.
1, FL1-H) was above the bulk of negative cells. To restrict the
analysis to positive cells, two selection gates were drawn above
negative cells transfected with a pCIneo vector (Promega) (Fig. 1A, i). The first gate (abef) included all positive green cells, and the second
gate (cdef) included only those cells with fluorescence intensities
exceeding about 1/10 of the highest values above background. Cell
brightness was different depending on the protein expressed, as the
maximum fluorescence due to native EGFP (Fig. 1A, iii and vi) was about
10-fold less than that of EG110 (Fig. 1A, iv to vii) or EGFXE (Fig. 1A,
v to viii). This correlated with immunofluorescence observations of
electroporated cells expressing these proteins (results not shown). The
differences in fluorescence intensity between EGFP and EG110 or EGFXE
are probably due to the diffuse nuclear and cytoplasmic distribution of
EGFP, compared to the concentrated localization of EG110 and EGFXE in
bright nuclear dots which initially correspond to the ND10 domains. The
heterogeneous distribution of the intensity of green fluorescence of
positive cells expressing a particular protein correlated with the
variability in the amount of expression observed from cell to cell by
immunofluorescence (data not shown).

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 1.
FACS analysis of cells expressing EGFP, EG110, or EGFXE.
HEp-2 cells were electroporated with plasmid pEGFP, pEG110, or pEGFXE
or with the control vector pCIneo. Cells were harvested (50,000 for
pEGFXE and pEGdl110-transfected cells; 100,000 for pEG110-transfected
cells) 17, 23, 27, and 30 h postelectroporation (pe) and checked
for their distribution in the cell cycle, using the LYSYS II software
(Becton Dickinson). (A) Dot plot diagrams of cells expressing EGFP (iii
and vi), EG110 (iv and vii), or EGFXE (v and viii) 17 (iii to v) and 30 (vi to viii) h postelectroporation. A dot plot diagram (i) and the
corresponding histogram (ii) obtained by the analysis of control cells
are also shown representing the distribution of control cells in the
cell cycle. The horizontal bar in histogram ii indicates the region
selected to determine the percentage of positive cells in
G2/M during the course of the experiment. Gate abef was
chosen for the analysis of the total number of cells positive for the
expression of an EGFP. Gate cdef restricted the analysis to cells which
were highly positive. (B and C) Analysis of the percentage of
G2/M cells expressing EGFP, EG110, or EGFXE in both gate
abef and gate cdef at 17, 23, 27, and 30 h posttransfection.
|
|
Figure
1A illustrates the distribution of positive EGFP-expressing
cells in the cell cycle at two time points corresponding
to 17 h
(T17) (iii to v) and 30 h (T30) (vi to viii) postelectroporation.
Seventeen hours postelectroporation positive cells were almost
all in
G
0/G
1 whatever the protein expressed. This
phenomenon is
probably due to the transfection itself, which might
result in
a block of transfected cells in G
0/G
1
until complete recovery
from the modifications undergone during the
transfection process.
Thirty hours postelectroporation, about 30% of
cells expressing
EGFP were in G
2/M (Fig.
1A, vi; Fig.
1B)
whereas two populations
of EG110-expressing cells could be
distinguished. On one hand,
cells expressing low amounts of EG110
(region abcd) were not affected
by the protein expression and seemed to
progress partially to
G
2/M (Fig.
1A, vii). On the other
hand, cells positive for higher
expression of EG110 (region cdef)
stayed almost entirely in G
1/S
(Fig.
1A, vii; compare Fig.
1B and C). Such a disparity was not
observed in EGFXE-expressing cells,
as they were able to progress
to G
2/M independently of the
level of expression of EGFXE (Fig.
1A, viii; compare Fig.
1B and C). A
putative lack of expression
or a rapid degradation of EG110 in cells in
S-G
2/M, which would
result in the absence of detection of
cells expressing high amounts
of EG110, was excluded by control
experiments. For example, FACS
analysis showed a high level of
expression of EG110 in cells in
G
2/M when synchronized
cells were transfected in S-G
2/M by using
a liposomal
reagent (results not
shown).
Since the selection gates were drawn on the basis of the results in
each individual experiment, it was not possible to present
averaged
results from different experiments. However, data presented
in Fig.
1B
and C are representative of multiple independent repeat
experiments.
They thus give a reliable summary of the actual effect
of each protein
on the progression of cells to the S phase of
the cell cycle. Figures
1B and C represent the percentage of cells
in G
2/M (Fig.
1A, ii, gate G
2/M) during the course of an experiment
either among the entire population of positive cells (Fig.
1A,
gate
abef) or among cells positive for higher expression of EG110
or EGFXE
(Fig.
1A, gate cdef). The total number of EGFP-expressing
cells (gate
abef) was used as a control in both graphs, as the
distribution of
positive cells was similar in both gates. Figure
1B shows that
progression of positive cells from G
1/S to G
2/M
in gate abcd during the course of the experiment is slightly affected
by the expression of EG110 or EGFXE in comparison with EGFP alone.
However, whereas the percentage of G
2/M cells positive for
the
expression of EGFXE is exactly the same in both gates (about 22%
at T30), high EG110-expressing cells are dramatically affected
in their
progression from G
1/S to G
2/M (only about 5%
of positive
cells in G
2/M at T30) (Fig.
1C). These results
show that Vmw110
is able to block cell cycle progression from
G
1 to S-G
2/M; however,
its activity is clearly
dependent on the amount of protein expressed
in the cell, and the RING
finger domain makes an important contribution
to this
effect.
Vmw110 is not the only viral factor implicated in the block of
infected cells at the G1/S border of the cell cycle.
To analyze whether Vmw110 might by itself cause the previously observed
block of infected cells at the G1/S border and to specifically analyze cells which had been successfully infected, FACS
analyses were performed on synchronized HEp-2 cells infected with virus
vEG110, vEGFXE, or vEGdl110, expressing EGFP fusion protein
linked to wild-type or FXE Vmw110 or to EGFP in place of Vmw110,
respectively. The construction and properties of these viruses are
summarized in Materials and Methods and Table 1. Synchronized cells
were infected at different stages during the G1 phase prior
to entry into S phase, and their DNA content was measured by FACS at
different times after infection. Before embarking on this experiment,
we analyzed the progression of uninfected cells through the cell cycle
after release from G0/G1-S block by aphidicolin
over a period of 24 h (Fig. 2A). The
distribution of the cell population in the cycle was determined by
analyzing their DNA content by FACS and by measuring the percentage of
cells in G0/G1, S, and G2/M. To
confirm that cells were cycling correctly, the amounts of both cyclin
B1 and cyclin E were monitored by Western blotting during the whole
period (Fig. 2B). From the time of release onward, the level of cyclin
E decreases in accordance with the cells moving from S into
G2/M. After a 10-h period (T10) cells consistently enter
mitosis, which correlates with the peak in the amount of cyclin B1, and
the whole population completes mitosis by 14 h postrelease. Then,
from T16 to T21 the majority of cells (about 75%) are in
G1 and reenter S phase about 22 to 24 h postrelease (as confirmed by the increase of the level of cyclin E at T24). Cells
were thus infected at T18, T20, T21, T22, and T24, and infections were
stopped at T27, when a high proportion of cells would normally have
progressed to S-G2.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 2.
Progression of aphidicolin-synchronized HEp-2 cells
through the cell cycle. HEp-2 cells were blocked in
G0/G1-S by aphidicolin and monitored for
24 h after release to follow their progression through the cell
cycle. Each hour cells were harvested, and their DNA content was
analyzed by FACS to determine their position in the cell cycle (A). (B)
Western blotting following the variation in the amount of both cyclin
B1 and cyclin E during the course of the experiment.
|
|
As the EFGPs are easily detectable by fluorescence 3 h
postinfection and EG110 and EGFXE are already present at the ND10
domains
at this time (results not shown), T27 was considered a suitable
time to analyze by FACS the DNA content of infected cells in comparison
with mock-infected cells (Fig.
3A).
The G
2/M peak of cells infected
by any of the three viruses
disappeared in cells infected early
in G
1 (T18 to T20)
which suggests that the earlier cells are infected
before the beginning
of S phase, the less chance they have to
progress from G
1
into S. Figure
3B shows the percentage of infected
green cells still in
G
1 at T27, depending on their infection time
postrelease.
The results show that (i) the ability of cells infected
just before
(T21) or at the start of (T22 and T24) S phase to
move from
G
1 into S is not reduced by the infection, (ii) compared
to
mock-infected cells, a slight increase of infected cells still
in
G
1 is noticeable when cells were infected at T20, but there
were no differences between the three viruses, and (iii) the percentage
of T18-infected cells still in G
1 is dramatically increased
compared
to the mock-infected cells, but once again without any
differences
between the viruses. By infecting cells that early before
the
start of S phase, we obviously cannot rule out the possibility
that
viral DNA replication had already started by the time cells
reached the
G
1/S border, which would undoubtedly affect cell cycle
progression. Taken with the results of Fig.
1, these experiments
suggest that although Vmw110 is able to block G
1-to-S phase
progression
by itself, other viral proteins expressed during infection
are
able to do so, as shown by the results obtained with the
Vmw110-deficient
mutants. Furthermore, this experiment shows that the
time of infection
before the start of S phase is important for the
block to be efficient.
These data are in complete agreement with
previous observations
(
7) and suggest that there is a
critical point during G
1 beyond
which infection by HSV-1
will not lead to the block of infected
cells at the G
1/S
boundary, as shown by the absence of any block
of cells infected at T21
to T24. It follows that the G
1/S block
caused by Vmw110 in
electroporated cells requires that Vmw110
be expressed in greater
amounts or for longer periods than occurred
in the infections initiated
at T21 to T24.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 3.
FACS analysis of the progression of HSV-1-infected HEp-2
cells from G1 into S phase of the cell cycle.
Aphidicolin-synchronized cells were mock infected or infected with
vEG110, vEGFXE, or vEGdl110 (MOI of 5 to 10) at 18 (T18), 20 (T20), 21 (T21), 22 (T22), and 24 (T24) h postrelease for 9 (t9), 7 (t7), 6 (t6), 5 (t5), or 3 (t3) h, respectively. Cells were then
harvested 27 h (T27) postrelease to measure the amount of infected
cells still in G1 compared to mock-infected cells. A gate
was selected on the total cell data to specifically analyze green
fluorescent (infected) cells. (A) DNA distribution of mock-infected and
infected synchronized HEp-2 cells 27 h after release from
aphidicolin block. (B) Percentage of cells in G1 at T27
depending on the infection time postrelease. mock-t0 represents
mock-infected cells at the time of infection corresponding to 24 (T24),
22 (T22), 21 (T21), 20 (T20), and 18 (T18) hours postrelease; mock-T27,
vEG110, vEGFXE, and vEGdl110 represent mock-, vEG110-,
vEGFXE-, and vEGdl110-infected cells at T27, respectively.
|
|
Synchronized cells infected during S-G2 phase of the
cell cycle do not efficiently progress through mitosis.
It has
recently been shown that the centromeric protein CENP-C, a component of
the inner plate of kinetochores which plays a key role in chromatid
separation during mitosis (for a review, see reference
39), is degraded by a proteasome and
Vmw110-dependent mechanism in cells infected by HSV-1 (17).
These data led us to investigate in greater detail than described
previously whether the degradation of CENP-C by Vmw110 could affect the
progression of infected cells through mitosis. Synchronized HEp-2 cells
were infected 7 h postrelease from an aphidicolin block (T7), when about 80% of the cells are in S-G2 (Fig. 2A), and then
analyzed by FACS. To specifically analyze cells that were successfully infected the vEG110, vEGFXE, and vEGdl110 viruses were used.
The DNA profiles of either infected or mock-infected HEp-2 cells during the course of the experiment and the percentages of cells still in
G2/M at various times after infection are represented in
Fig. 4A and B, respectively. Whereas
mock-infected cells were going through mitosis between 10 and 11 h
postrelease, a high percentage of cells infected with vEG110 remained
in G2/M 15 h postrelease. Such a dramatic effect was
not observed in cells infected with either vEGFXE or
vEGdl110, which suggested that Vmw110 was specifically implicated in the block of infected cells in G2/M. However
there was a slight delay in vEGFXE- and vEGdl110-infected
cells progressing through mitosis, suggesting that infection itself
might slow down (but not block) the progression of cells from
G2/M to G1. This observation is in accordance
with the higher amount of mock-infected than of infected cells in
G1 seen at T10 (Fig. 4A). The lower portion of the peak of
vEG110-infected cells in G1 at T15 seems atypically
enlarged (compare vEG110 T15 with Mock T15, vEGFXE T15, and
vEGdl110 T15 in Fig. 4A), which suggests that a
subpopulation of these infected cells might contain an abnormal amount
of DNA (see below). An important factor in the interpretation of this experiment is that the development of infection in HEp-2 cells is
comparatively slow, so that few cells have developed replication centers at these times (data not shown). It would be expected that in
cells in which DNA replication is established more quickly, consequential chromosomal damage would in any case halt cell cycle progression.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 4.
FACS analysis of the progression of infected cells from
G2/M to G1. HEp-2 cells were blocked in
G0/G1-S by aphidicolin and released for 7 h before being infected by vEG110, vEGFXE, or vEGdl110 (MOI
of 10). Cells were harvested at 10 (T10), 11 (T11), 13 (T13), and 15 (T15) h postrelease, which corresponded to 3 (t3), 4 (t4), 6 (t6), and
8 (t8) h postinfection. The progression of mock-infected and infected
cells from G2/M to G1 was followed by monitoring their DNA
content by FACS as shown by the histograms (A). The percentage of cells
in G2/M was then determined at each time point (B). mock,
vEG110, vEGFXE, and vEGdl110 represent mock-, vEG110-,
vEGFXE-, and vEGdl110-infected cells, respectively.
|
|
Cells infected by viruses expressing either EG110 or Vmw110 are
blocked between prophase and metaphase stages of mitosis.
To
analyze in detail the effect of infection on synchronized cells,
fluorescence microscopy was performed on cells that were infected
similarly to the above experiment. Cell DNA was stained by PI to
visualize the distribution of the DNA in infected cells during the
course of the experiment. Strikingly, 4 h postinfection, cells
infected at T7 by vEG110 started to accumulate at an unusual stage of
mitosis, and these cells constituted a high proportion of the total
cell population 8 h postinfection (Fig.
5A). These cells showed an atypical
chromosome distribution between prophase and prometaphase identical to
that observed for cells infected in the same conditions by wild-type
HSV-1 (Fig. 5B and C). A similar phenotype, called pseudo-prometaphase,
has already been described by Bernat et al. (3) for mitotic
cells which were microinjected with anticentromere antibodies at a
suitable time before the start of mitosis. The atypical chromosome
distribution phenotype observed in our experiments will thus be
referred as to pseudo-prometaphase in accordance to the terminology
used in that paper. Extremely few cells infected by either vEG110 or
wild-type HSV-1 (not shown) could be seen in metaphase or anaphase, but
some were proceeding to cytokinesis despite chromosomal DNA still being
present at the cleavage furrow (Fig. 5H). This observation was specific
for cells infected with these viruses, as mock-infected (not shown) as
well as vEGFXE (or FXE [not shown])- or vEGdl110 (or
dl1403 [not shown])-infected cells did not show these
phenotypes and were easily found in metaphase (Fig. 5D and F), at
anaphase (Fig. 5E and G), and in normal cytokinesis, as shown as an
example for a vEGdl110-infected cell (Fig. 5I). The abnormal
cytokinesis of vEG110-infected cells would most likely lead to
aneuploid micronucleated daughter cells with an aberrant DNA content
(see reference 17), which might explain the
broadening of the peak corresponding to vEG110-infected cells in
G1 at T15 observed by FACS analysis (Fig. 4A, vEG110 T15).

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 5.
Confocal microscopy analysis of infected mitotic cells.
HEp-2 cells were synchronized as described previously and infected
7 h postrelease with either vEG110 or wild-type HSV-1 or with
vEGFXE or vEGdl110 (MOI of 10). Eight hours postinfection,
cells were harvested, treated with PI (0.5 µg/ml) (red), and then
examined by fluorescence microscopy. Vmw110 in cells infected with
wild-type HSV-1 (B and C) was detected by immunofluorescence according
to the protocol described in reference 17. (A and B)
Cells infected with vEG110 and wild-type HSV-1, respectively, with
their chromosomes stalled in pseudo-prometaphase; (C) detailed view of
the chromosome distribution defined as pseudo-prometaphase; (D to G)
cells infected with vEGFXE (green staining due to EGFXE) or
vEGdl110 (green staining due to EGFP). Unlike cells infected
with vEG110 or wild-type HSV-1, vEGFXE- and
vEGdl110-infected cells can be easily found in the normal
stages of metaphase (D and F), anaphase (E and G), or cytokinesis
(shown as an example for a vEGdl110-infected cell [I]).
Panel H shows a vEG110-infected cell going through cytokinesis although
its DNA is still present at the cleavage furrow. This cell shows a
close association of EG110 with the edges of the chromatin staining at
this stage of mitosis. The scale bars represent 5 µm.
|
|
The block of infected cells at the pseudo-prometaphase stage is
specific of Vmw110 expression.
To quantify the effect
described above, the percentage of cells in mitosis, in
prophase/pseudo-prometaphase, and in metaphase/anaphase was
calculated for mock-infected cells and for cells infected with
wild-type (17 syn+ strain), FXE, or dl1403 virus. A
methodology similar to that described above was used, in that HEp-2
cells were synchronized, infected at 7 h after release from the
aphidicolin block, and then fixed for examination at various times
thereafter. DNA was stained with PI, and infected cells were detected
by using MAb 11060 (anti-Vmw110) for cells infected with the wild-type and FXE viruses and MAb 58S (anti-Vmw175) for
dl1403-infected cells. Each parameter was measured by
analyzing by immunofluorescence of three fields of cells taken
randomly, using the 40× objective lens of the microscope (between 150 and 300 cells/field). Averages were calculated, and the results are
shown in Fig.
6.
The overall percentage of mitotic cells clearly accumulated in cells
infected with the wild-type virus compared to mock-infected cells or
cells infected with the Vmw110 mutant viruses (Fig. 6A). The analysis of their mitotic stages showed that 8 h postinfection, about 40% of cells were stalled in prophase/pseudo-prometaphase (Fig. 6B) and
very few (<1%) were in metaphase/anaphase (Fig. 6C). Eight hours
postinfection, FXE- and dl1403-infected cells still in
mitosis were almost all in metaphase/anaphase, and in no cases did
cells in prophase show a phenotype similar to the pseudo-prometaphase phenotype (Fig. 5A and B). Mock-infected cells showed a normal mitotic
distribution during the course of the experiment. These results
demonstrate that Vmw110 is directly implicated in the block of infected
cells in an early stage of mitosis between prophase and metaphase. This
effect is clearly dependent on Vmw110 and more precisely on the RING
finger domain of Vmw110, as the FXE mutant virus does not block cells
at the pseudo-prometaphase stage.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 6.
Analysis of the distribution of infected mitotic cells
in different stages of mitosis. Synchronized HEp-2 cells 7 h after
release from the aphidicolin block were mock infected (mock) or
infected with wild-type HSV-1 (17 syn+ [17+]), Vmw110 deletion mutant
dl1403, or a virus expressing the RING finger deletion
mutant of Vmw110 (FXE) (MOI of 10). At various times after infection,
immunofluorescence was performed with an anti-Vmw110 antibody to detect
cells infected with either 17 syn+ or FXE or with an anti-Vmw175
antibody for cells infected with dl1403. DNA was stained by
PI (0.5 µg/ml). Percentages of mitotic cells were determined at 4 (t4), 5 (t5), 6 (t6), and 8 (t8) h postinfection by counting three
fields of cells taken randomly, using the 40× optical lens and by
calculating the average results. Panels A, B, and C represent the
percentages of cells being in any stages of mitosis, in
prophase/pseudo-prometaphase, and in metaphase/anaphase,
respectively.
|
|
 |
DISCUSSION |
We have shown in this study that Vmw110 affects both the
G1-to-S and the G2/M-to-G1
transitions of the cell cycle. The progression of cells through the
cell cycle is a complex process involving interactions between positive
and negative regulators whose activities are dependent on a variety of
both intra- and extracellular stimuli. These activities regulate, among
other things, cellular DNA replication and division which constitute
two major cell transformations responsible for the transmission of
genetic information from a cell to its daughters. These two aspects of
the cell cycle are strictly regulated to avoid any malfunction to be
transmitted from generation to generation. In that respect key events,
which have been extensively documented, are responsible for the cell to
progress beyond checkpoints leading to either DNA replication or mitosis.
A large number of proteins and protein modifications are implicated in
the G1-to-S transition of the cell cycle, and the product of the retinoblastoma tumor suppressor gene, pRb, plays a central role
in the achievement of that process (for a review see reference 54). Activation of cyclin-dependent kinases (cdks)
by G1 cyclins, among which are cyclins of the D class (D1,
D2, and D3) and cyclin E, leads to the inactivation of pRb by
hyperphosphorylation resulting in, among other events, the release of
active transcription factor E2F. Many S-phase-specific genes are then
activated by E2F to allow entry of the cell into S phase (for reviews,
see references 22, 27, 28, 49, and
54). Once cells enter S phase, cyclin E is degraded
and cdk2, which earlier in the cycle associates with cyclin E, forms
complexes with cyclin A.
Viral oncoproteins such as simian virus 40 T antigen, adenovirus E1A,
and human papillomavirus E7, facilitate the G1-S transition by binding to pRb and releasing E2F. Systematic studies on the effects
of HSV-1 infection on this particular stage of the cell cycle have not
yet been reported, although some relevant data are available. Previous
data have shown that synchronized CV-1 cells infected by HSV-1 in
G1 were unable to progress to S phase (7).
However, multiple protein activities might be affected during the pre-S
phase entry, which would prevent infected cells progressing beyond the
G1/S phase boundary. Interestingly, Hilton et al.
(21) showed that HSV-1 infection of asynchronous cultures of
C33A cells induces DNA binding activities of both free E2F and the
p107/E2F heterodimer. These data might seem contradictory, as an
increase in free E2F would stimulate S phase entry whereas by forming a
heterodimer with E2F, p107 blocks E2F activity. However, as suggested
by the authors, it is reasonable to assume that efficient HSV-1 DNA
replication might require cellular factors that are expressed in late
G1 just prior to cellular DNA replication. If so, the
virus-induced block of entry into S phase would be expected to be after
the stage of E2F-activated late G1 functions. One other key
component of G1-to-S phase progression that has been studied in the context of virus infection is cyclin D3. Kawaguchi et
al. (26) reported the partial degradation of cyclin D3 by HSV-1 in Vero cells infected for 8 h, by a process that was
accelerated by the absence of Vmw110. However, although cyclin D3 is
implicated in the phosphorylation of pRb, the results described by
Hilton et al. (21) suggest that it is unlikely that its
downregulation would prevent infected cells reaching the
G1/S border. Thus, it is also unlikely that the interaction
of Vmw110 with cyclin D3 (26) directly accounts for the
G1/S block of EG110-expressing transfected cells observed
in our study.
In addition to these data, it has also recently been shown that the use
of specific inhibitors of cdks which are required for
G1-to-S phase progression results in considerable
inhibition of IE and E transcription and HSV-1 replication (46,
47). It was suggested that cdk-activated cellular and/or viral
transcription factors might be required for optimal transcriptional
activation of the viral genome. All of these data show that HSV-1 is
able to influence and is influenced by some key events occurring in G1/S, a critical phase of the cell cycle beyond which cells
are irreversibly committed to mitosis. Our current results show that Vmw110 is likely to affect some factors implicated in that decision resulting in the block of the G1-to-S transition, an effect
partly dependent on the RING finger domain of the protein. However, the ability of viruses either deficient for the expression of Vmw110 (vEGdl110) or expressing the RING finger mutant of the
protein (vEGFXE) to block infected cells in G1/S suggests
that viral proteins other than Vmw110 also cause a G1/S
block. Moreover, an efficient block of infected cells at the
G1/S border is observed only when cells are infected early
enough before the onset of S phase (reference 7 and
this study). Therefore the G1-S block observed in
transfected cells expressing Vmw110 is likely to occur only after
Vmw110 has been present for a number of hours, and during this time in
a normal infection other viral factors could also block the cell cycle
at this stage.
This study also shows that infection by HSV-1 is able to block cells at
the mitotic stage of the cell cycle. Of great interest is that, unlike
the G1/S block, this mitotic block is specifically due to
Vmw110 and more precisely to its RING finger domain, as mutant viruses
unable to express Vmw110 (dl1403 and vEG110) or expressing
the RING finger Vmw110 mutant protein (FXE and vEGFXE) do not retain
this activity. This function of Vmw110 can be related to recent work
which showed that Vmw110 induces the proteasome-dependent degradation
of the centromeric protein CENP-C (17). Indeed, it has
previously been shown that microinjection of anticentromere antibodies
in cells about to reach mitosis was able either to significantly delay
mitosis or block chromosome distribution in an atypical stage of
mitosis called pseudo-prometaphase (3, 4). The observations
made in our study are fully consistent with those obtained by the
microinjection of anticentromere antibodies, as HSV-1 induces similar
pseudo-prometaphase distribution of chromosomes and delay of mitosis.
However, microinjection of anti-CENP-C antibodies early enough before
the beginning of mitosis results in a metaphase block (52),
which suggests that the inhibition of CENP-C alone is not sufficient to
generate a pseudo-prometaphase arrest. Therefore, in addition to
CENP-C, the stability of other centromeric proteins might be affected
by Vmw110 in HSV-1-infected cells. An interesting prediction from our
findings is that cells infected at an appropriate stage in
G2 with wild-type HSV-1 may not produce progeny virus. Indeed, the infected cells stalled in pseudo-prometaphase lack a
nuclear envelope, and it seems highly likely that viral transcription, DNA replication and maturation would be severely compromised.
During the last decade, the development of therapies aiming to use
virus-based vectors as delivery systems has opened new fields of
interest for HSV-1. However, although its ability to persist in hosts
for very long time makes it a good candidate for permanent gene
expression, its high degree of toxicity in infected cells is
incompatible with the use of unmodified parental genomes as vector
systems. In order to reduce the toxicity of such vectors,
replication-defective mutants of HSV-1 have been constructed with
multiple deletions in genes encoding proteins affecting cell survival.
Deletion of one or several IE genes coding for proteins implicated in
virus replication dramatically decreased the vector toxicity (1,
23, 24, 37, 38, 44, 56), but survival of cells infected by these
vectors was still significantly affected unless all five IE proteins
were absent (45). More specifically, Wu et al.
(56) suggested a putative role for Vmw110 in the inhibition
of both cellular DNA synthesis and the division potential of the cells.
The data presented in our study provide an explanation for these
suggestions, as we showed that Vmw110 expression in infected cells
would affect both pathways resulting in an incompatibility between
Vmw110 expression and survival of a cell population. These data also
partly explain both the failure to establish cell lines constitutively
expressing Vmw110 and the remaining toxicity of any
replication-defective mutants of HSV-1 still able to express Vmw110.
Therefore, the aberrations in mitotic events likely due to the
degradation of CENP-C exclude the expression of Vmw110 in any
HSV-1-based vectors used for stable expression of foreign proteins in
gene therapy of dividing cells. Over the past few years, several
independent studies emphasized the possible effects of the expression
of Vmw110 on cell metabolism and/or survival. Our study shows that
expression of Vmw110 in cycling cells will affect both
G1-to-S and G2/M-to-G1 transitions,
undoubtedly creating physiological changes, which would eventually lead
to cell death.
 |
ACKNOWLEDGMENTS |
We are grateful to Alan Mowat for collaboration in the use of the
FACS, to the Department of Clinical Immunology for use of the
equipment, to Elizabeth Allen and Susana de la Luna for helpful constructive criticisms, and to Duncan McGeoch for support.
This work was supported by the Medical Research Council. P.L. is a
postdoctoral researcher funded by a European Community training project
(Marie Curie research training grant) financed by the European
Commission under the Biomedicine and Health Fourth Framework Programme.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: MRC Virology
Unit, Institute of Virology, Church St., Glasgow G11 5JR, Scotland,
United Kingdom. Phone: 44 0 141 330 6299. Fax: 44 0 141 337 2236. E-mail: p.lomonte{at}vir.gla.ac.uk.
 |
REFERENCES |
| 1.
|
Ace, C. I.,
T. A. McKee,
J. M. Ryan,
J. M. Cameron, and C. M. Preston.
1989.
Construction and characterization of herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression.
J. Virol.
63:2260-2269[Abstract/Free Full Text].
|
| 2.
|
Ascoli, C. A., and G. G. Maul.
1991.
Identification of a novel nuclear domain.
J. Cell Biol.
112:785-795[Abstract/Free Full Text].
|
| 3.
|
Bernat, R. L.,
G. G. Borisy,
N. F. Rothchild, and W. C. Earnshaw.
1990.
Injection of anti-centromere antibodies in interphase disrupts events required for chromosome movement at mitosis.
J. Cell Biol.
111:1519-1533[Abstract/Free Full Text].
|
| 4.
|
Bernat, R. L.,
M. R. Delannoy,
N. F. Rothfield, and W. C. Earnshaw.
1991.
Disruption of centromere assembly during interphase inhibits kinetochore morphogenesis and function in mitosis.
Cell
66:1229-1238[Medline].
|
| 5.
|
Cai, W.,
T. D. Astor,
L. M. Liptak,
C. Cho,
D. Coen, and P. A. Schaffer.
1993.
The herpes simplex virus type 1 regulatory protein ICP0 enhances replication during acute infection and reactivation from latency.
J. Virol.
67:7501-7512[Abstract/Free Full Text].
|
| 6.
|
Clements, J. B., and N. D. Stow.
1989.
A herpes simplex virus type 1 mutant containing a deletion within immediate-early gene 1 is latency competent in mice.
J. Gen. Virol.
70:2501-2506[Abstract/Free Full Text].
|
| 7.
|
De Bruyn Kops, A., and D. M. Knipe.
1988.
Formation of DNA replication structures in herpes virus-infected cells requires a viral DNA binding protein.
Cell
55:857-868[Medline].
|
| 8.
|
DeLuca, N. M.,
M. A. Courtney, and P. A. Schaffer.
1984.
Temperature-sensitive mutants in herpes simplex virus type 1 ICP4 permissive for early gene expression.
J. Virol.
52:767-776[Abstract/Free Full Text].
|
| 9.
|
Dixon, R. A. F., and P. A. Schaffer.
1980.
Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175.
J. Virol.
36:189-203[Abstract/Free Full Text].
|
| 10.
|
Earnshaw, W. C., and N. Rothfield.
1985.
Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma.
Chromosoma
91:313-321[Medline].
|
| 11.
|
Everett, R. D.
1989.
Construction and characterisation of herpes simplex virus type 1 mutants with defined lesions in immediate-early gene 1.
J. Gen. Virol.
70:1185-1202[Abstract/Free Full Text].
|
| 12.
|
Everett, R. D.,
C. M. Preston, and N. D. Stow.
1991.
Functional and genetic analysis of the role of Vmw110 in herpes simplex virus replication, p. 50-76.
In
E. K. Wagner (ed.), The control of herpes simplex virus gene expression. CRC Press Inc., Boca Raton, Fla.
|
| 13.
|
Everett, R. D.,
A. Cross, and A. Orr.
1993.
A truncated form of herpes simplex virus type 1 immediate-early protein Vmw110 is expressed in a cell-type dependent manner.
Virology
197:751-756[Medline].
|
| 14.
|
Everett, R. D.,
M. R. Meredith,
A. Orr,
A. Cross,
M. Kathoria, and J. Parkinson.
1997.
A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.
EMBO J.
16:1519-1530[Medline].
|
| 15.
|
Everett, R. D.,
P. Freemont,
H. Saitoh,
M. Dasso,
A. Orr,
M. Kathoria, and J. Parkinson.
1998.
The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110 and proteasome-dependent loss of several PML isoforms.
J. Virol.
72:6581-6591[Abstract/Free Full Text].
|
| 16.
|
Everett, R. D.,
A. Orr, and C. M. Preston.
1998.
A viral activator of gene expression functions via the ubiquitin-proteasome pathway.
EMBO J.
17:7161-7169[Medline].
|
| 17.
|
Everett, R. D.,
W. C. Earnshaw,
J. Findlay, and P. Lomonte.
1999.
Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110.
EMBO J.
18:1526-1538[Medline].
|
| 18.
|
Fields, B. N.,
D. M. Knipe, and P. M. Howley.
1996.
Virology, 3rd ed., vol. 2.
Lippincott-Raven, Philadelphia, Pa.
|
| 19.
|
Fraser, N. W.,
T. M. Block, and J. G. Spivack.
1992.
The latency associated transcripts of herpes simplex virus: RNA in search of a function.
Virology
191:1-8[Medline].
|
| 20.
|
Harris, R. A.,
R. D. Everett,
X. Zhu,
S. Silverstein, and C. M. Preston.
1989.
The herpes simplex virus (HSV) immediate-early protein Vmw110 reactivates latent HSV type 2 in an in vitro latency system.
J. Virol.
63:3513-3515[Abstract/Free Full Text].
|
| 21.
|
Hilton, M. J.,
D. Mounghane,
T. McLean,
N. V. Contractor,
J. O'Neil,
K. Carpenter, and S. L. Bachenheimer.
1995.
Induction by herpes simplex virus of free and heteromeric forms of E2F transcription factor.
Virology
213:624-638[Medline].
|
| 22.
|
Hunter, T., and J. Pines.
1994.
Cyclins and cancer II: cyclin D and CDK inhibitors come of age.
Cell
79:573-582[Medline].
|
| 23.
|
Johnson, P. A.,
A. Miyanohara,
F. Levine,
T. Cahill, and T. Friedmann.
1992.
Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1.
J. Virol.
66:2952-2965[Abstract/Free Full Text].
|
| 24.
|
Johnson, P. A.,
M. J. Wang, and T. Friedmann.
1994.
Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function.
J. Virol.
68:6347-6362[Abstract/Free Full Text].
|
| 25.
|
Kawaguchi, Y.,
R. Bruni, and B. Roizman.
1997.
Interaction of herpes simplex virus 1 regulatory protein ICP0 with elongation factor 1 : ICP0 affects translation machinery.
J. Virol.
71:1019-1024[Abstract].
|
| 26.
|
Kawaguchi, Y.,
C. Van Sant, and B. Roizman.
1997.
Herpes simplex type 1 regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3.
J. Virol.
71:7328-7336[Abstract].
|
| 27.
|
Lam, E. W.-F., and N. B. La Thangue.
1994.
DP and E2F proteins: coordinating transcription with cell cycle progression.
Curr. Opin. Cell Biol.
6:859-866[Medline].
|
| 28.
|
La Thangue, N. B.
1994.
DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control.
Trends Biochem. Sci.
19:108-114[Medline].
|
| 29.
|
Lees-Miller, S. P.,
M. C. Long,
M. A. Kilvert,
V. Lam,
S. A. Rice, and C. A. Spencer.
1996.
Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0.
J. Virol.
70:7471-7477[Abstract].
|
| 30.
|
Leib, D. A.,
D. M. Coen,
C. L. Bogard,
K. A. Hicks,
D. R. Yager,
D. M. Knipe,
K. L. Tyler, and P. A. Schaffer.
1989.
Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency.
J. Virol.
63:759-768[Abstract/Free Full Text].
|
| 31.
| Lomonte, P., and R. D. Everett. Unpublished
data.
|
| 32.
|
McCarthy, A. M.,
L. McMahan, and P. A. Schaffer.
1989.
Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient.
J. Virol.
63:18-27[Abstract/Free Full Text].
|
| 33.
|
Meredith, M. R.,
A. Orr, and R. D. Everett.
1994.
Herpes simplex virus type 1 immediate-early protein Vmw110 binds strongly and specifically to a 135kD cellular protein.
Virology
200:457-469[Medline].
|
| 34.
|
Parkinson, J.,
S. P. Lees-Miller, and R. D. Everett.
1999.
Herpes simplex virus type 1 immediate-early protein Vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase.
J. Virol.
73:650-657[Abstract/Free Full Text].
|
| 35.
|
Post, L. E., and B. Roizman.
1981.
A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus type 1 is not essential for growth.
Cell
25:227-232[Medline].
|
| 36.
|
Preston, C. M.
1979.
Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsk.
J. Virol.
29:228-239.
|
| 37.
|
Preston, C. M., and M. J. Nicholl.
1997.
Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis.
J. Virol.
71:7807-7813[Abstract].
|
| 38.
|
Preston, C. M.,
R. Mabbs, and M. J. Nicholl.
1997.
Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression.
Virology
229:228-239[Medline].
|
| 39.
|
Rieder, C. L., and E. D. Salmon.
1998.
The vertebrate cell kinetochore and its roles during mitosis.
Trends Cell Biol.
8:310-318.
[Medline] |
| 40.
|
Roizman, B., and A. E. Sears.
1996.
Herpes simplex viruses and their replication, p. 2231-2296.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Raven Press, New York, N.Y.
|
| 41.
|
Sacks, W. R.,
C. C. Greene,
D. P. Aschman, and P. A. Schaffer.
1985.
Herpes simplex virus type 1 ICP27 is an essential regulatory protein.
J. Virol.
55:796-805[Abstract/Free Full Text].
|
| 42.
|
Sacks, W. R., and P. A. Schaffer.
1987.
Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture.
J. Virol.
61:829-839[Abstract/Free Full Text].
|
| 43.
|
Saitoh, H.,
J. Tomkiel,
C. A. Cooke,
H. Ratrie,
M. Maurer,
N. F. Rothfield, and W. C. Earnshaw.
1992.
CENP-C, and autoantigen in scleroderma, is a component of the human inner kinetochore plate.
Cell
70:115-125[Medline].
|
| 44.
|
Samaniego, L. A.,
N. Wu, and N. A. DeLuca.
1997.
The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27.
J. Virol.
71:4614-4625[Abstract].
|
| 45.
|
Samaniego, L. A.,
L. Neiderhiser, and N. A. DeLuca.
1998.
Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins.
J. Virol.
72:3307-3320[Abstract/Free Full Text].
|
| 46.
|
Schang, L. M.,
J. Phillips, and P. A. Schaffer.
1998.
Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
J. Virol.
72:5626-5637[Abstract/Free Full Text].
|
| 47.
|
Schang, L. M.,
A. Rosenberg, and P. A. Schaffer.
1999.
Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.
J. Virol.
73:2161-2172[Abstract/Free Full Text].
|
| 48.
|
Sears, A. E.,
I. W. Halliburton,
B. Meignier,
S. Silver, and B. Roizman.
1985.
Herpes simplex virus 1 mutant deleted in the 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice.
J. Virol.
55:338-346[Abstract/Free Full Text].
|
| 49.
|
Sherr, C. J.
1994.
G1 phase progression: cycling on cue.
Cell
79:551-555[Medline].
|
| 50.
|
Showalter, L. D.,
M. Zweig, and B. Hampar.
1981.
Monoclonal antibodies to herpes simplex type 1 proteins including the immediate-early protein ICP4.
Infect. Immun.
34:684-692[Abstract/Free Full Text].
|
| 51.
|
Stow, N. D., and E. C. Stow.
1986.
Isolation and characterisation of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate-early polypeptide Vmw110.
J. Gen. Virol.
67:2571-2585[Abstract/Free Full Text].
|
| 52.
|
Tomkiel, J.,
C. A. Cooke,
H. Saitoh,
R. Bernat, and W. C. Earnshaw.
1994.
CENP-C is required for maintaining proper kinetochore size and for a timely transition to anaphase.
J. Cell Biol.
125:531-545[Abstract/Free Full Text].
|
| 53.
|
Watson, R. J., and J. B. Clements.
1978.
Characterization of transcription-deficient temperature-sensitive mutants of herpes simplex virus type 1.
Virology
91:364-379[Medline].
|
| 54.
|
Weinberg, R. A.
1995.
The retinoblastoma protein and cell cycle control.
Cell
81:323-330[Medline].
|
| 55.
|
Wilcox, C. L.,
R. L. Smith,
R. D. Everett, and D. Mysofski.
1997.
The herpes simplex virus type 1 immediate-early ICP0 is necessary for the efficient establishment of latent infection.
J. Virol.
71:6777-6785[Abstract].
|
| 56.
|
Wu, N.,
S. C. Watkins,
P. A. Schaffer, and N. A. DeLuca.
1996.
Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22.
J. Virol.
70:6358-6369[Abstract].
|
| 57.
|
Zhu, X.,
J. Chen,
C. S. H. Young, and S. Silverstein.
1990.
Reactivation of latent herpes simplex virus by adenovirus recombinants encoding mutant IE-0 gene products.
J. Virol.
64:4489-4498[Abstract/Free Full Text].
|
Journal of Virology, November 1999, p. 9456-9467, Vol. 73, No. 11
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Everett, R. D., Parsy, M.-L., Orr, A.
(2009). Analysis of the Functions of Herpes Simplex Virus Type 1 Regulatory Protein ICP0 That Are Critical for Lytic Infection and Derepression of Quiescent Viral Genomes. J. Virol.
83: 4963-4977
[Abstract]
[Full Text]
-
Daubeuf, S., Singh, D., Tan, Y., Liu, H., Federoff, H. J., Bowers, W. J., Tolba, K.
(2009). HSV ICP0 recruits USP7 to modulate TLR-mediated innate response. Blood
113: 3264-3275
[Abstract]
[Full Text]
-
Calle, A., Ugrinova, I., Epstein, A. L., Bouvet, P., Diaz, J.-J., Greco, A.
(2008). Nucleolin Is Required for an Efficient Herpes Simplex Virus Type 1 Infection. J. Virol.
82: 4762-4773
[Abstract]
[Full Text]
-
Nguyen, M. L., Kraft, R. M., Aubert, M., Goodwin, E., DiMaio, D., Blaho, J. A.
(2007). p53 and hTERT Determine Sensitivity to Viral Apoptosis. J. Virol.
81: 12985-12995
[Abstract]
[Full Text]
-
Terry-Allison, T., Smith, C. A., DeLuca, N. A.
(2007). Relaxed Repression of Herpes Simplex Virus Type 1 Genomes in Murine Trigeminal Neurons. J. Virol.
81: 12394-12405
[Abstract]
[Full Text]
-
Morency, E., Sabra, M., Catez, F., Texier, P., Lomonte, P.
(2007). A novel cell response triggered by interphase centromere structural instability. JCB
177: 757-768
[Abstract]
[Full Text]
-
Kummer, M., Turza, N. M., Muhl-Zurbes, P., Lechmann, M., Boutell, C., Coffin, R. S., Everett, R. D., Steinkasserer, A., Prechtel, A. T.
(2007). Herpes Simplex Virus Type 1 Induces CD83 Degradation in Mature Dendritic Cells with Immediate-Early Kinetics via the Cellular Proteasome. J. Virol.
81: 6326-6338
[Abstract]
[Full Text]
-
Zhang, Y., Jiang, Y., Geiser, V., Zhou, J., Jones, C.
(2006). Bovine herpesvirus 1 immediate-early protein (bICP0) interacts with the histone acetyltransferase p300, which stimulates productive infection and gC promoter activity. J. Gen. Virol.
87: 1843-1851
[Abstract]
[Full Text]
-
Bringhurst, R. M., Schaffer, P. A.
(2006). Cellular Stress Rather than Stage of the Cell Cycle Enhances the Replication and Plating Efficiencies of Herpes Simplex Virus Type 1 ICP0- Viruses. J. Virol.
80: 4528-4537
[Abstract]
[Full Text]
-
Surjit, M., Liu, B., Chow, V. T. K., Lal, S. K.
(2006). The Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus Inhibits the Activity of Cyclin-Cyclin-dependent Kinase Complex and Blocks S Phase Progression in Mammalian Cells. J. Biol. Chem.
281: 10669-10681
[Abstract]
[Full Text]
-
Orlando, J. S., Astor, T. L., Rundle, S. A., Schaffer, P. A.
(2006). The Products of the Herpes Simplex Virus Type 1 Immediate-Early US1/US1.5 Genes Downregulate Levels of S-Phase-Specific Cyclins and Facilitate Virus Replication in S-Phase Vero Cells.. J. Virol.
80: 4005-4016
[Abstract]
[Full Text]
-
Walisko, O., Izsvak, Z., Szabo, K., Kaufman, C. D., Herold, S., Ivics, Z.
(2006). Sleeping Beauty transposase modulates cell-cycle progression through interaction with Miz-1.. Proc. Natl. Acad. Sci. USA
103: 4062-4067
[Abstract]
[Full Text]
-
Geiser, V., Zhang, Y., Jones, C.
(2005). Analysis of a bovine herpesvirus 1 recombinant virus that does not express the bICP0 protein. J. Gen. Virol.
86: 1987-1996
[Abstract]
[Full Text]
-
Zhang, Y., Zhou, J., Jones, C.
(2005). Identification of functional domains within the bICP0 protein encoded by bovine herpesvirus 1. J. Gen. Virol.
86: 879-886
[Abstract]
[Full Text]
-
Geoffroy, M.-C., Epstein, A. L., Toublanc, E., Moullier, P., Salvetti, A.
(2004). Herpes Simplex Virus Type 1 ICP0 Protein Mediates Activation of Adeno-Associated Virus Type 2 rep Gene Expression from a Latent Integrated Form. J. Virol.
78: 10977-10986
[Abstract]
[Full Text]
-
Chen, C.-J., Sugiyama, K., Kubo, H., Huang, C., Makino, S.
(2004). Murine Coronavirus Nonstructural Protein p28 Arrests Cell Cycle in G0/G1 Phase. J. Virol.
78: 10410-10419
[Abstract]
[Full Text]
-
Li, Y.-H., Tao, P.-Z., Liu, Y.-Z., Jiang, J.-D.
(2004). Geldanamycin, a Ligand of Heat Shock Protein 90, Inhibits the Replication of Herpes Simplex Virus Type 1 In Vitro. Antimicrob. Agents Chemother.
48: 867-872
[Abstract]
[Full Text]
-
Everett, R. D., Boutell, C., Orr, A.
(2004). Phenotype of a Herpes Simplex Virus Type 1 Mutant That Fails To Express Immediate-Early Regulatory Protein ICP0. J. Virol.
78: 1763-1774
[Abstract]
[Full Text]
-
Davido, D. J., von Zagorski, W. F., Maul, G. G., Schaffer, P. A.
(2003). The Differential Requirement for Cyclin-Dependent Kinase Activities Distinguishes Two Functions of Herpes Simplex Virus Type 1 ICP0. J. Virol.
77: 12603-12616
[Abstract]
[Full Text]
-
Boutell, C., Everett, R. D.
(2003). The Herpes Simplex Virus Type 1 (HSV-1) Regulatory Protein ICP0 Interacts with and Ubiquitinates p53. J. Biol. Chem.
278: 36596-36602
[Abstract]
[Full Text]
-
Izumiya, Y., Lin, S.-F., Ellison, T. J., Levy, A. M., Mayeur, G. L., Izumiya, C., Kung, H.-J.
(2003). Cell Cycle Regulation by Kaposi's Sarcoma-Associated Herpesvirus K-bZIP: Direct Interaction with Cyclin-CDK2 and Induction of G1 Growth Arrest. J. Virol.
77: 9652-9661
[Abstract]
[Full Text]
-
Burton, E. A., Hong, C.-S., Glorioso, J. C.
(2003). The Stable 2.0-Kilobase Intron of the Herpes Simplex Virus Type 1 Latency-Associated Transcript Does Not Function as an Antisense Repressor of ICP0 in Nonneuronal Cells. J. Virol.
77: 3516-3530
[Abstract]
[Full Text]
-
Everett, R. D., Sourvinos, G., Orr, A.
(2003). Recruitment of Herpes Simplex Virus Type 1 Transcriptional Regulatory Protein ICP4 into Foci Juxtaposed to ND10 in Live, Infected Cells. J. Virol.
77: 3680-3689
[Abstract]
[Full Text]
-
Wu, F. Y., Chen, H., Wang, S. E., apRhys, C. M. J., Liao, G., Fujimuro, M., Farrell, C. J., Huang, J., Hayward, S. D., Hayward, G. S.
(2002). CCAAT/Enhancer Binding Protein {alpha} Interacts with ZTA and Mediates ZTA-Induced p21CIP-1 Accumulation and G1 Cell Cycle Arrest during the Epstein-Barr Virus Lytic Cycle. J. Virol.
77: 1481-1500
[Abstract]
[Full Text]
-
Mauser, A., Holley-Guthrie, E., Zanation, A., Yarborough, W., Kaufmann, W., Klingelhutz, A., Seaman, W. T., Kenney, S.
(2002). The Epstein-Barr Virus Immediate-Early Protein BZLF1 Induces Expression of E2F-1 and Other Proteins Involved in Cell Cycle Progression in Primary Keratinocytes and Gastric Carcinoma Cells. J. Virol.
76: 12543-12552
[Abstract]
[Full Text]
-
Mauser, A., Holley-Guthrie, E., Simpson, D., Kaufmann, W., Kenney, S.
(2002). The Epstein-Barr Virus Immediate-Early Protein BZLF1 Induces both a G2 and a Mitotic Block. J. Virol.
76: 10030-10037
[Abstract]
[Full Text]
-
Evers, D. L., Breitenbach, J. M., Borysko, K. Z., Townsend, L. B., Drach, J. C.
(2002). Inhibition of Cyclin-Dependent Kinase 1 by Purines and Pyrrolo[2,3-d]Pyrimidines Does Not Correlate with Antiviral Activity. Antimicrob. Agents Chemother.
46: 2470-2476
[Abstract]
[Full Text]
-
Moxley, M. J., Block, T. M., Liu, H.-C., Fraser, N. W., Perng, G.-C., Wechsler, S. L., Su, Y.-H.
(2002). Herpes simplex virus type 1 infection prevents detachment of nerve growth factor-differentiated PC12 cells in culture. J. Gen. Virol.
83: 1591-1600
[Abstract]
[Full Text]
-
Davido, D. J., Leib, D. A., Schaffer, P. A.
(2002). The Cyclin-Dependent Kinase Inhibitor Roscovitine Inhibits the Transactivating Activity and Alters the Posttranslational Modification of Herpes Simplex Virus Type 1 ICP0. J. Virol.
76: 1077-1088
[Abstract]
[Full Text]
-
Boutell, C., Sadis, S., Everett, R. D.
(2002). Herpes Simplex Virus Type 1 Immediate-Early Protein ICP0 and Its Isolated RING Finger Domain Act as Ubiquitin E3 Ligases In Vitro. J. Virol.
76: 841-850
[Abstract]
[Full Text]
-
Zhang, Y., Jones, C.
(2001). The Bovine Herpesvirus 1 Immediate-Early Protein (bICP0) Associates with Histone Deacetylase 1 To Activate Transcription. J. Virol.
75: 9571-9578
[Abstract]
[Full Text]
-
Halford, W. P., Kemp, C. D., Isler, J. A., Davido, D. J., Schaffer, P. A.
(2001). ICP0, ICP4, or VP16 Expressed from Adenovirus Vectors Induces Reactivation of Latent Herpes Simplex Virus Type 1 in Primary Cultures of Latently Infected Trigeminal Ganglion Cells. J. Virol.
75: 6143-6153
[Abstract]
[Full Text]
-
Flemington, E. K.
(2001). Herpesvirus Lytic Replication and the Cell Cycle: Arresting New Developments. J. Virol.
75: 4475-4481
[Full Text]
-
Hobbs, W. E., Brough, D. E., Kovesdi, I., DeLuca, N. A.
(2001). Efficient Activation of Viral Genomes by Levels of Herpes Simplex Virus ICP0 Insufficient To Affect Cellular Gene Expression or Cell Survival. J. Virol.
75: 3391-3403
[Abstract]
[Full Text]
-
Inman, M., Zhang, Y., Geiser, V., Jones, C.
(2001). The zinc ring finger in the bICP0 protein encoded by bovine herpesvirus-1 mediates toxicity and activates productive infection. J. Gen. Virol.
82: 483-492
[Abstract]
[Full Text]
-
Everett, R. D.
(2000). ICP0 Induces the Accumulation of Colocalizing Conjugated Ubiquitin. J. Virol.
74: 9994-10005
[Abstract]
[Full Text]
-
Advani, S. J., Weichselbaum, R. R., Roizman, B.
(2000). E2F Proteins Are Posttranslationally Modified Concomitantly with a Reduction in Nuclear Binding Activity in Cells Infected with Herpes Simplex Virus 1. J. Virol.
74: 7842-7850
[Abstract]
[Full Text]
-
Hoge, A. T., Hendrickson, S. B., Burns, W. H.
(2000). Murine Gammaherpesvirus 68 Cyclin D Homologue Is Required for Efficient Reactivation from Latency. J. Virol.
74: 7016-7023
[Abstract]
[Full Text]
-
Spencer, C. A., Kruhlak, M. J., Jenkins, H. L., Sun, X., Bazett-Jones, D. P.
(2000). Mitotic Transcription Repression in Vivo in the Absence of Nucleosomal Chromatin Condensation. JCB
150: 13-26
[Abstract]
[Full Text]
-
Lomonte, P., Sullivan, K. F., Everett, R. D.
(2001). Degradation of Nucleosome-associated Centromeric Histone H3-like Protein CENP-A Induced by Herpes Simplex Virus Type 1 Protein ICP0. J. Biol. Chem.
276: 5829-5835
[Abstract]
[Full Text]